

Product Data Sheet

Product Name: Sermorelin (acetate)

Cat. No.: GC49592

Chemical Properties

Cas. No. 516482-86-3

SMILES NC([C@H](CCCCNC(N)=N)NC([C@H](CO)NC([C@@H](NC([C@@]([C@H](CC)C)([H])NC([C@@H](NC([C@H](CCC(N)=O)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CCCCNC(N)=N)NC([C@@H](NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CCC(N)=O)NC(CNC([C@H](CC(C)C)NC([C@H](C(C)C)NC([C@H](CCCCN)NC([C@H](CCCCNC(N)=N)NC([C@@H](NC([C@H](CO)NC([C@H](CC(N)=O)NC([C@@]([C@@H](C)O)([H])NC([C@@H](NC([C@@]([C@H](CC)C)([H])NC([C@@H](NC([C@@H](NC([C@@H](N[H])CC1=CC=C(O)C=C1)=O)C)=O)CC(O)=O)=O)C)=O)=O)CC2=CC=CC=C2)=O)=O)=O)CC3=CC=C(O)C=C3)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC(O)=O)=O)CCSC)=O)=O.O.CC(O)=O

Formula C₁₄₉H₂₄₆N₄₄O₄₂S • XC₂H₄O₂ M.Wt 3357.9

Solubility Water: 1 mg/ml Storage -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
 • XCH₃CO₂H

Background

Sermorelin is a 29-residue N-terminal analog of growth hormone-releasing hormone (GHRH) that retains the ability to stimulate growth hormone (GH) release.¹ Sermorelin (1 µg/kg, i.v.) increases

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

serum GH levels in rats by approximately 17% compared with saline control after 15 minutes.² It also increases GH release in pigs when administered at a dose of 250 ng/kg.³ Sermorelin (1 μ M) increases proliferation of NCI-H727 human bronchial carcinoid cells by 30% and increases vascular endothelial growth factor (VEGF) secretion.⁴ It increases phosphorylation of focal adhesion kinase (FAK) and expression of VEGF in A549 lung cancer cells when used at a concentration of 0.1 μ M.⁵ Formulations containing sermorelin have been used to diagnose and treat growth hormone deficiency.

1.Rivier, J., Spiess, J., Thorner, M., et al.Characterization of a growth hormone-releasing factor from a human pancreatic islet tumourNature300(5889)276-278(1982) 2.Izdebski, J., Pinski, J., Horvath, J.E., et al.Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormoneProc. Natl. Acad. Sci. USA92(11)4872-4876(1995) 3.Lance, V.A., Murphy, W.A., Sueiras-Diaz, J., et al.Super-active analogs of growth hormone-releasing factor (1-29)-amideBiochem. Bioph. Res. Commun.119(1)265-272(1984) 4.Stepie, T., Sacewicz, M., Lawnicka, H., et al.Stimulatory effect of growth hormone-releasing hormone (GHRH(1-29)NH₂) on the proliferation, VEGF and chromogranin A secretion by human neuroendocrine tumor cell line NCI-H727 in vitroNeuropeptides43(5)397-400(2009) 5.Siejka, A., Barabutis, N., and Schally, A.V.GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitroPeptides37(1)63-68(2012)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA